Artal Group S.A. Aravive, Inc. Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.2 - $1.83 $3.91 Million - $5.97 Million	3,261,224 Added 248.7%	4,572,515 $6.04 Million
Q3 2020 Nov 13, 2020	SELL	$4.7 - $12.06 $324,370 - $832,320	-69,015 Reduced 5.0%	1,311,291 $6.16 Million
Q2 2020 Aug 14, 2020	SELL	$5.18 - $14.81 $361,014 - $1.03 Million	-69,694 Reduced 4.81%	1,380,306 $16.1 Million
Q1 2020 May 14, 2020	BUY	$3.5 - $13.77 $350,000 - $1.38 Million	100,000 Added 7.41%	1,450,000 $8.35 Million
Q4 2019 Feb 13, 2020	BUY	$6.21 - $14.02 $5.9 Million - $13.3 Million	950,000 Added 237.5%	1,350,000 $18.5 Million
Q3 2019 Nov 14, 2019	BUY	$5.2 - $8.68 $481,176 - $803,195	92,534 Added 30.1%	400,000 $3 Million
Q2 2019 Aug 09, 2019	BUY	$5.65 - $7.5 $289,263 - $383,977	51,197 Added 19.98%	307,466 $1.85 Million
Q1 2019 May 10, 2019	BUY	$3.35 - $8.27 $858,501 - $2.12 Million	256,269 New	256,269 $1.8 Million

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.